Ophthalmic Drugs - Global Market Outlook (2020-2028)
According to Stratistics MRC, the Global Ophthalmic Drugs market is accounted for $36.70 billion in 2020 and is expected to reach $70.49 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Some of the key factors propelling the market growth include rising R&D pertaining to the development of novel drugs, increasing focus on developing combination therapies, rising advancements in technologies, favorable reimbursement policies, increasing accessibility for healthcare facilities, and increasing incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. However, loss of patent protection for popular drugs is restraining the market growth.
Ophthalmic drugs are used to treat eye infection and various types of eye conditions. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. Ophthalmic diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, retinal vein occlusion (RVO), and myopic choroidal neovascularization, are potential threats to an individual’s sight. Ophthalmic drug forms have been one of the most important and widely developed areas of pharmaceutical technology over the few years.
By indication, the dry eye segment is anticipated to grow at the significant rate during the forecast period, increased dry eye cases among the peoples. Dry eye disease (DED) is a multifactorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to ageing, and hence, it remains an under-researched condition in the low%li%and middle-income countries. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the ageing population and the adoption of modern lifestyle.
On the basis of geography, the Asia Pacific is estimated to be the fastest-growing region in the market over the forecast period, due to increasing burden of ophthalmic disorders and rising consumer awareness. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the clinical and experimental vision and eye research, India, 2018. Moreover, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth.
Some of the key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.
Types Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Ophthalmic drugs are used to treat eye infection and various types of eye conditions. These are used in the treatment of dry eye, age-related macular degeneration, diabetic retinopathy, and other eye disorders. Ophthalmic diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, retinal vein occlusion (RVO), and myopic choroidal neovascularization, are potential threats to an individual’s sight. Ophthalmic drug forms have been one of the most important and widely developed areas of pharmaceutical technology over the few years.
By indication, the dry eye segment is anticipated to grow at the significant rate during the forecast period, increased dry eye cases among the peoples. Dry eye disease (DED) is a multifactorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to ageing, and hence, it remains an under-researched condition in the low%li%and middle-income countries. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the ageing population and the adoption of modern lifestyle.
On the basis of geography, the Asia Pacific is estimated to be the fastest-growing region in the market over the forecast period, due to increasing burden of ophthalmic disorders and rising consumer awareness. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the clinical and experimental vision and eye research, India, 2018. Moreover, increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth.
Some of the key players in Ophthalmic Drugs Market include Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.
Types Covered:
- Over-the-Counter Drugs
- Prescription Drugs
- Drug Delivery
- Gene Therapy
- Biologics
- Small Molecule
- Cell Therapy
- Generic Drugs
- Branded Drugs
- Glaucoma
- Dry Eye
- Cataract
- Retinal Disorders
- Uveitis
- Eye Infection/Inflammation/Eye Allergy
- Allergic Conjunctivitis
- Age-Related Macular Degeneration (AMD)
- Diabetic Eye Disease
- Other Indications
- Drug Stores
- Hospital Pharmacies
- Online Pharmacies
- Eye Health Clinics
- Retail Pharmacies/Independent Pharmacies
- Systemic
- Local Ocular
- Topical
- Oral
- Parenteral
- Solid Ophthalmic Drug Forms
- Liquid Ophthalmic Drug Forms
- Multicompartment Drug Delivery Systems
- Semisolid Ophthalmic Drug Forms
- Eye Solutions
- Capsules & Tablets
- Eye Ointment
- Gels
- Eye Drops
- Anti-Inflammatory
- Antibiotics
- Anti-Allergy
- Anti-Glaucoma Drugs
- Anti-Angiogenic
- Anti-Infective Drugs
- Anti-Vascular Endothelial Growth Factor (VEGF) Agents
- Retinal Drug
- Other Therapeutic Classes (Cyclosporine)
- Specialty Clinics
- Hospitals
- Pharmacy
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2019, 2020, 2021, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE
5.1 Introduction
5.2 Over-the-Counter Drugs
5.3 Prescription Drugs
6 GLOBAL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY
6.1 Introduction
6.2 Drug Delivery
6.3 Gene Therapy
6.4 Biologics
6.5 Small Molecule
6.6 Cell Therapy
7 GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG VARIATION
7.1 Introduction
7.2 Generic Drugs
7.3 Branded Drugs
8 GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION
8.1 Introduction
8.2 Glaucoma
8.3 Dry Eye
8.4 Cataract
8.5 Retinal Disorders
8.5.1 Diabetic Retinopathy
8.5.2 Macular Degeneration
8.5.2.1 Dry Age-Related Macular Degeneration
8.5.2.2 Wet Age-Related Macular Degeneration
8.6 Uveitis
8.7 Eye Infection/Inflammation/Eye Allergy
8.8 Allergic Conjunctivitis
8.9 Age-Related Macular Degeneration (AMD)
8.10 Diabetic Eye Disease
8.11 Other Indications
8.11.1 Eyelash Hypotrichosis
8.11.2 Optic Neuropathy
9 GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
9.1 Introduction
9.2 Drug Stores
9.3 Hospital Pharmacies
9.4 Online Pharmacies
9.5 Eye Health Clinics
9.6 Retail Pharmacies/Independent Pharmacies
10 GLOBAL OPHTHALMIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
10.1 Introduction
10.2 Systemic
10.3 Local Ocular
10.3.1 Retrobulbar
10.3.2 Subconjunctival
10.3.3 Intracameral
10.3.4 Intravitreal
10.4 Topical
10.5 Oral
10.6 Parenteral
11 GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM
11.1 Introduction
11.2 Solid Ophthalmic Drug Forms
11.3 Liquid Ophthalmic Drug Forms
11.4 Multicompartment Drug Delivery Systems
11.5 Semisolid Ophthalmic Drug Forms
12 GLOBAL OPHTHALMIC DRUGS MARKET, BY DELIVERY TYPE
12.1 Introduction
12.2 Eye Solutions
12.3 Capsules & Tablets
12.4 Eye Ointment
12.5 Gels
12.6 Eye Drops
13 GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS
13.1 Introduction
13.2 Anti-Inflammatory
13.2.1 Steroidal Drugs
13.2.2 Non-Steroidal Anti-Inflammatory drugs (NSAIDs)
13.3 Antibiotics
13.4 Anti-Allergy
13.5 Anti-Glaucoma Drugs
13.5.1 Prostaglandin Analogs
13.5.2 Combined Medication
13.5.3 Alpha Agonist
13.5.4 Beta-Blockers
13.6 Anti-Angiogenic
13.7 Anti-Infective Drugs
13.7.1 Anti-Fungal Drugs
13.7.2 Anti-Bacterial Drugs
13.7.3 Anti-Viral Drugs
13.8 Anti-Vascular Endothelial Growth Factor (VEGF) Agents
13.9 Retinal Drug
13.10 Other Therapeutic Classes (Cyclosporine)
14 GLOBAL OPHTHALMIC DRUGS MARKET, BY END USER
14.1 Introduction
14.2 Specialty Clinics
14.3 Hospitals
14.4 Pharmacy
15 GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY
15.1 Introduction
15.2 North America
15.2.1 US
15.2.2 Canada
15.2.3 Mexico
15.3 Europe
15.3.1 Germany
15.3.2 UK
15.3.3 Italy
15.3.4 France
15.3.5 Spain
15.3.6 Rest of Europe
15.4 Asia Pacific
15.4.1 Japan
15.4.2 China
15.4.3 India
15.4.4 Australia
15.4.5 New Zealand
15.4.6 South Korea
15.4.7 Rest of Asia Pacific
15.5 South America
15.5.1 Argentina
15.5.2 Brazil
15.5.3 Chile
15.5.4 Rest of South America
15.6 Middle East & Africa
15.6.1 Saudi Arabia
15.6.2 UAE
15.6.3 Qatar
15.6.4 South Africa
15.6.5 Rest of Middle East & Africa
16 KEY DEVELOPMENTS
16.1 Agreements, Partnerships, Collaborations and Joint Ventures
16.2 Acquisitions & Mergers
16.3 New Product Launch
16.4 Expansions
16.5 Other Key Strategies
17 COMPANY PROFILING
17.1 Bayer AG
17.2 Abbott Healthcare
17.3 Merck & Co.
17.4 Pfizer, Inc.
17.5 Novartis AG
17.6 Valeant Pharmaceuticals, Inc.
17.7 Johnson & Johnson
17.8 Allergan Plc
17.9 Santen Pharmaceutical Co. Ltd.
17.10 Genentech, Inc.
17.11 F. Hoffmann-La Roche Ltd
17.12 Regeneron Pharmaceuticals Inc.
17.13 Aerie Pharmaceuticals Inc.
17.14 Bausch Health Companies Inc.
17.15 Carl-Zeiss AG
17.16 Hoya Corporation
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE
5.1 Introduction
5.2 Over-the-Counter Drugs
5.3 Prescription Drugs
6 GLOBAL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY
6.1 Introduction
6.2 Drug Delivery
6.3 Gene Therapy
6.4 Biologics
6.5 Small Molecule
6.6 Cell Therapy
7 GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG VARIATION
7.1 Introduction
7.2 Generic Drugs
7.3 Branded Drugs
8 GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION
8.1 Introduction
8.2 Glaucoma
8.3 Dry Eye
8.4 Cataract
8.5 Retinal Disorders
8.5.1 Diabetic Retinopathy
8.5.2 Macular Degeneration
8.5.2.1 Dry Age-Related Macular Degeneration
8.5.2.2 Wet Age-Related Macular Degeneration
8.6 Uveitis
8.7 Eye Infection/Inflammation/Eye Allergy
8.8 Allergic Conjunctivitis
8.9 Age-Related Macular Degeneration (AMD)
8.10 Diabetic Eye Disease
8.11 Other Indications
8.11.1 Eyelash Hypotrichosis
8.11.2 Optic Neuropathy
9 GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
9.1 Introduction
9.2 Drug Stores
9.3 Hospital Pharmacies
9.4 Online Pharmacies
9.5 Eye Health Clinics
9.6 Retail Pharmacies/Independent Pharmacies
10 GLOBAL OPHTHALMIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
10.1 Introduction
10.2 Systemic
10.3 Local Ocular
10.3.1 Retrobulbar
10.3.2 Subconjunctival
10.3.3 Intracameral
10.3.4 Intravitreal
10.4 Topical
10.5 Oral
10.6 Parenteral
11 GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM
11.1 Introduction
11.2 Solid Ophthalmic Drug Forms
11.3 Liquid Ophthalmic Drug Forms
11.4 Multicompartment Drug Delivery Systems
11.5 Semisolid Ophthalmic Drug Forms
12 GLOBAL OPHTHALMIC DRUGS MARKET, BY DELIVERY TYPE
12.1 Introduction
12.2 Eye Solutions
12.3 Capsules & Tablets
12.4 Eye Ointment
12.5 Gels
12.6 Eye Drops
13 GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS
13.1 Introduction
13.2 Anti-Inflammatory
13.2.1 Steroidal Drugs
13.2.2 Non-Steroidal Anti-Inflammatory drugs (NSAIDs)
13.3 Antibiotics
13.4 Anti-Allergy
13.5 Anti-Glaucoma Drugs
13.5.1 Prostaglandin Analogs
13.5.2 Combined Medication
13.5.3 Alpha Agonist
13.5.4 Beta-Blockers
13.6 Anti-Angiogenic
13.7 Anti-Infective Drugs
13.7.1 Anti-Fungal Drugs
13.7.2 Anti-Bacterial Drugs
13.7.3 Anti-Viral Drugs
13.8 Anti-Vascular Endothelial Growth Factor (VEGF) Agents
13.9 Retinal Drug
13.10 Other Therapeutic Classes (Cyclosporine)
14 GLOBAL OPHTHALMIC DRUGS MARKET, BY END USER
14.1 Introduction
14.2 Specialty Clinics
14.3 Hospitals
14.4 Pharmacy
15 GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY
15.1 Introduction
15.2 North America
15.2.1 US
15.2.2 Canada
15.2.3 Mexico
15.3 Europe
15.3.1 Germany
15.3.2 UK
15.3.3 Italy
15.3.4 France
15.3.5 Spain
15.3.6 Rest of Europe
15.4 Asia Pacific
15.4.1 Japan
15.4.2 China
15.4.3 India
15.4.4 Australia
15.4.5 New Zealand
15.4.6 South Korea
15.4.7 Rest of Asia Pacific
15.5 South America
15.5.1 Argentina
15.5.2 Brazil
15.5.3 Chile
15.5.4 Rest of South America
15.6 Middle East & Africa
15.6.1 Saudi Arabia
15.6.2 UAE
15.6.3 Qatar
15.6.4 South Africa
15.6.5 Rest of Middle East & Africa
16 KEY DEVELOPMENTS
16.1 Agreements, Partnerships, Collaborations and Joint Ventures
16.2 Acquisitions & Mergers
16.3 New Product Launch
16.4 Expansions
16.5 Other Key Strategies
17 COMPANY PROFILING
17.1 Bayer AG
17.2 Abbott Healthcare
17.3 Merck & Co.
17.4 Pfizer, Inc.
17.5 Novartis AG
17.6 Valeant Pharmaceuticals, Inc.
17.7 Johnson & Johnson
17.8 Allergan Plc
17.9 Santen Pharmaceutical Co. Ltd.
17.10 Genentech, Inc.
17.11 F. Hoffmann-La Roche Ltd
17.12 Regeneron Pharmaceuticals Inc.
17.13 Aerie Pharmaceuticals Inc.
17.14 Bausch Health Companies Inc.
17.15 Carl-Zeiss AG
17.16 Hoya Corporation
LIST OF TABLES
Table 1 Global Ophthalmic Drugs Market Outlook, By Region (2019-2028) ($MN)
Table 2 Global Ophthalmic Drugs Market Outlook, By Type (2019-2028) ($MN)
Table 3 Global Ophthalmic Drugs Market Outlook, By Over-the-Counter Drugs (2019-2028) ($MN)
Table 4 Global Ophthalmic Drugs Market Outlook, By Prescription Drugs (2019-2028) ($MN)
Table 5 Global Ophthalmic Drugs Market Outlook, By Technology (2019-2028) ($MN)
Table 6 Global Ophthalmic Drugs Market Outlook, By Drug Delivery (2019-2028) ($MN)
Table 7 Global Ophthalmic Drugs Market Outlook, By Gene Therapy (2019-2028) ($MN)
Table 8 Global Ophthalmic Drugs Market Outlook, By Biologics (2019-2028) ($MN)
Table 9 Global Ophthalmic Drugs Market Outlook, By Small Molecule (2019-2028) ($MN)
Table 10 Global Ophthalmic Drugs Market Outlook, By Cell Therapy (2019-2028) ($MN)
Table 11 Global Ophthalmic Drugs Market Outlook, By Drug Variation (2019-2028) ($MN)
Table 12 Global Ophthalmic Drugs Market Outlook, By Generic Drugs (2019-2028) ($MN)
Table 13 Global Ophthalmic Drugs Market Outlook, By Branded Drugs (2019-2028) ($MN)
Table 14 Global Ophthalmic Drugs Market Outlook, By Indication (2019-2028) ($MN)
Table 15 Global Ophthalmic Drugs Market Outlook, By Glaucoma (2019-2028) ($MN)
Table 16 Global Ophthalmic Drugs Market Outlook, By Dry Eye (2019-2028) ($MN)
Table17 Global Ophthalmic Drugs Market Outlook, By Cataract (2019-2028) ($MN)
Table 18 Global Ophthalmic Drugs Market Outlook, By Retinal Disorders (2019-2028) ($MN)
Table 19 Global Ophthalmic Drugs Market Outlook, By Diabetic Retinopathy (2019-2028) ($MN)
Table 20 Global Ophthalmic Drugs Market Outlook, By Macular Degeneration (2019-2028) ($MN)
Table 21 Global Ophthalmic Drugs Market Outlook, By Uveitis (2019-2028) ($MN)
Table 22 Global Ophthalmic Drugs Market Outlook, By Eye Infection/Inflammation/Eye Allergy (2019-2028) ($MN)
Table 23 Global Ophthalmic Drugs Market Outlook, By Allergic Conjunctivitis (2019-2028) ($MN)
Table 24 Global Ophthalmic Drugs Market Outlook, By Age-Related Macular Degeneration (AMD) (2019-2028) ($MN)
Table 25 Global Ophthalmic Drugs Market Outlook, By Diabetic Eye Disease (2019-2028) ($MN)
Table 26 Global Ophthalmic Drugs Market Outlook, By Other Indications (2019-2028) ($MN)
Table 27 Global Ophthalmic Drugs Market Outlook, By Eyelash Hypotrichosis (2019-2028) ($MN)
Table 28 Global Ophthalmic Drugs Market Outlook, By Optic Neuropathy (2019-2028) ($MN)
Table 29 Global Ophthalmic Drugs Market Outlook, By Distribution Channel (2019-2028) ($MN)
Table 30 Global Ophthalmic Drugs Market Outlook, By Drug Stores (2019-2028) ($MN)
Table 31 Global Ophthalmic Drugs Market Outlook, By Hospital Pharmacies (2019-2028) ($MN)
Table 32 Global Ophthalmic Drugs Market Outlook, By Online Pharmacies (2019-2028) ($MN)
Table 33 Global Ophthalmic Drugs Market Outlook, By Eye Health Clinics (2019-2028) ($MN)
Table 34 Global Ophthalmic Drugs Market Outlook, By Retail Pharmacies/Independent Pharmacies (2019-2028) ($MN)
Table 35 Global Ophthalmic Drugs Market Outlook, By Route of Administration (2019-2028) ($MN)
Table 36 Global Ophthalmic Drugs Market Outlook, By Systemic (2019-2028) ($MN)
Table 37 Global Ophthalmic Drugs Market Outlook, By Local Ocular (2019-2028) ($MN)
Table 38 Global Ophthalmic Drugs Market Outlook, By Retrobulbar (2019-2028) ($MN)
Table 39 Global Ophthalmic Drugs Market Outlook, By Subconjunctival (2019-2028) ($MN)
Table 40 Global Ophthalmic Drugs Market Outlook, By Intracameral (2019-2028) ($MN)
Table 41 Global Ophthalmic Drugs Market Outlook, By Intravitreal (2019-2028) ($MN)
Table 42 Global Ophthalmic Drugs Market Outlook, By Topical (2019-2028) ($MN)
Table 43 Global Ophthalmic Drugs Market Outlook, By Oral (2019-2028) ($MN)
Table 44 Global Ophthalmic Drugs Market Outlook, By Parenteral (2019-2028) ($MN)
Table 45 Global Ophthalmic Drugs Market Outlook, By Dosage Form (2019-2028) ($MN)
Table 46 Global Ophthalmic Drugs Market Outlook, By Solid Ophthalmic Drug Forms (2019-2028) ($MN)
Table 47 Global Ophthalmic Drugs Market Outlook, By Liquid Ophthalmic Drug Forms (2019-2028) ($MN)
Table 48 Global Ophthalmic Drugs Market Outlook, By Multicompartment Drug Delivery Systems (2019-2028) ($MN)
Table 49 Global Ophthalmic Drugs Market Outlook, By Semisolid Ophthalmic Drug Forms (2019-2028) ($MN)
Table 50 Global Ophthalmic Drugs Market Outlook, By Delivery Type (2019-2028) ($MN)
Table 51 Global Ophthalmic Drugs Market Outlook, By Eye Solutions (2019-2028) ($MN)
Table 52 Global Ophthalmic Drugs Market Outlook, By Capsules & Tablets (2019-2028) ($MN)
Table 53 Global Ophthalmic Drugs Market Outlook, By Eye Ointment (2019-2028) ($MN)
Table 54 Global Ophthalmic Drugs Market Outlook, By Gels (2019-2028) ($MN)
Table 55 Global Ophthalmic Drugs Market Outlook, By Eye Drops (2019-2028) ($MN)
Table 56 Global Ophthalmic Drugs Market Outlook, By Therapeutic Class (2019-2028) ($MN)
Table 57 Global Ophthalmic Drugs Market Outlook, By Anti-Inflammatory (2019-2028) ($MN)
Table 58 Global Ophthalmic Drugs Market Outlook, By Steroidal Drugs (2019-2028) ($MN)
Table 59 Global Ophthalmic Drugs Market Outlook, By Non-Steroidal Anti-Inflammatory drugs (NSAIDs) (2019-2028) ($MN)
Table 60 Global Ophthalmic Drugs Market Outlook, By Antibiotics (2019-2028) ($MN)
Table 61 Global Ophthalmic Drugs Market Outlook, By Anti-Allergy (2019-2028) ($MN)
Table 62 Global Ophthalmic Drugs Market Outlook, By Anti-Glaucoma Drugs (2019-2028) ($MN)
Table 63 Global Ophthalmic Drugs Market Outlook, By Prostaglandin Analogs (2019-2028) ($MN)
Table 64 Global Ophthalmic Drugs Market Outlook, By Combined Medication (2019-2028) ($MN)
Table 65 Global Ophthalmic Drugs Market Outlook, By Alpha Agonist (2019-2028) ($MN)
Table 66 Global Ophthalmic Drugs Market Outlook, By Beta-Blockers (2019-2028) ($MN)
Table 67 Global Ophthalmic Drugs Market Outlook, By Anti-Angiogenic (2019-2028) ($MN)
Table 68 Global Ophthalmic Drugs Market Outlook, By Anti-Infective Drugs (2019-2028) ($MN)
Table 69 Global Ophthalmic Drugs Market Outlook, By Anti-Fungal Drugs (2019-2028) ($MN)
Table 70 Global Ophthalmic Drugs Market Outlook, By Anti-Bacterial Drugs (2019-2028) ($MN)
Table 71 Global Ophthalmic Drugs Market Outlook, By Anti-Viral Drugs (2019-2028) ($MN)
Table 72 Global Ophthalmic Drugs Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) Agents (2019-2028) ($MN)
Table 73 Global Ophthalmic Drugs Market Outlook, By Retinal Drug (2019-2028) ($MN)
Table 74 Global Ophthalmic Drugs Market Outlook, By Other Therapeutic Classes (Cyclosporine) (2019-2028) ($MN)
Table 75 Global Ophthalmic Drugs Market Outlook, By End User (2019-2028) ($MN)
Table 76 Global Ophthalmic Drugs Market Outlook, By Specialty Clinics (2019-2028) ($MN)
Table 77 Global Ophthalmic Drugs Market Outlook, By Hospitals (2019-2028) ($MN)
Table 78 Global Ophthalmic Drugs Market Outlook, By Pharmacy (2019-2028) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Table 1 Global Ophthalmic Drugs Market Outlook, By Region (2019-2028) ($MN)
Table 2 Global Ophthalmic Drugs Market Outlook, By Type (2019-2028) ($MN)
Table 3 Global Ophthalmic Drugs Market Outlook, By Over-the-Counter Drugs (2019-2028) ($MN)
Table 4 Global Ophthalmic Drugs Market Outlook, By Prescription Drugs (2019-2028) ($MN)
Table 5 Global Ophthalmic Drugs Market Outlook, By Technology (2019-2028) ($MN)
Table 6 Global Ophthalmic Drugs Market Outlook, By Drug Delivery (2019-2028) ($MN)
Table 7 Global Ophthalmic Drugs Market Outlook, By Gene Therapy (2019-2028) ($MN)
Table 8 Global Ophthalmic Drugs Market Outlook, By Biologics (2019-2028) ($MN)
Table 9 Global Ophthalmic Drugs Market Outlook, By Small Molecule (2019-2028) ($MN)
Table 10 Global Ophthalmic Drugs Market Outlook, By Cell Therapy (2019-2028) ($MN)
Table 11 Global Ophthalmic Drugs Market Outlook, By Drug Variation (2019-2028) ($MN)
Table 12 Global Ophthalmic Drugs Market Outlook, By Generic Drugs (2019-2028) ($MN)
Table 13 Global Ophthalmic Drugs Market Outlook, By Branded Drugs (2019-2028) ($MN)
Table 14 Global Ophthalmic Drugs Market Outlook, By Indication (2019-2028) ($MN)
Table 15 Global Ophthalmic Drugs Market Outlook, By Glaucoma (2019-2028) ($MN)
Table 16 Global Ophthalmic Drugs Market Outlook, By Dry Eye (2019-2028) ($MN)
Table17 Global Ophthalmic Drugs Market Outlook, By Cataract (2019-2028) ($MN)
Table 18 Global Ophthalmic Drugs Market Outlook, By Retinal Disorders (2019-2028) ($MN)
Table 19 Global Ophthalmic Drugs Market Outlook, By Diabetic Retinopathy (2019-2028) ($MN)
Table 20 Global Ophthalmic Drugs Market Outlook, By Macular Degeneration (2019-2028) ($MN)
Table 21 Global Ophthalmic Drugs Market Outlook, By Uveitis (2019-2028) ($MN)
Table 22 Global Ophthalmic Drugs Market Outlook, By Eye Infection/Inflammation/Eye Allergy (2019-2028) ($MN)
Table 23 Global Ophthalmic Drugs Market Outlook, By Allergic Conjunctivitis (2019-2028) ($MN)
Table 24 Global Ophthalmic Drugs Market Outlook, By Age-Related Macular Degeneration (AMD) (2019-2028) ($MN)
Table 25 Global Ophthalmic Drugs Market Outlook, By Diabetic Eye Disease (2019-2028) ($MN)
Table 26 Global Ophthalmic Drugs Market Outlook, By Other Indications (2019-2028) ($MN)
Table 27 Global Ophthalmic Drugs Market Outlook, By Eyelash Hypotrichosis (2019-2028) ($MN)
Table 28 Global Ophthalmic Drugs Market Outlook, By Optic Neuropathy (2019-2028) ($MN)
Table 29 Global Ophthalmic Drugs Market Outlook, By Distribution Channel (2019-2028) ($MN)
Table 30 Global Ophthalmic Drugs Market Outlook, By Drug Stores (2019-2028) ($MN)
Table 31 Global Ophthalmic Drugs Market Outlook, By Hospital Pharmacies (2019-2028) ($MN)
Table 32 Global Ophthalmic Drugs Market Outlook, By Online Pharmacies (2019-2028) ($MN)
Table 33 Global Ophthalmic Drugs Market Outlook, By Eye Health Clinics (2019-2028) ($MN)
Table 34 Global Ophthalmic Drugs Market Outlook, By Retail Pharmacies/Independent Pharmacies (2019-2028) ($MN)
Table 35 Global Ophthalmic Drugs Market Outlook, By Route of Administration (2019-2028) ($MN)
Table 36 Global Ophthalmic Drugs Market Outlook, By Systemic (2019-2028) ($MN)
Table 37 Global Ophthalmic Drugs Market Outlook, By Local Ocular (2019-2028) ($MN)
Table 38 Global Ophthalmic Drugs Market Outlook, By Retrobulbar (2019-2028) ($MN)
Table 39 Global Ophthalmic Drugs Market Outlook, By Subconjunctival (2019-2028) ($MN)
Table 40 Global Ophthalmic Drugs Market Outlook, By Intracameral (2019-2028) ($MN)
Table 41 Global Ophthalmic Drugs Market Outlook, By Intravitreal (2019-2028) ($MN)
Table 42 Global Ophthalmic Drugs Market Outlook, By Topical (2019-2028) ($MN)
Table 43 Global Ophthalmic Drugs Market Outlook, By Oral (2019-2028) ($MN)
Table 44 Global Ophthalmic Drugs Market Outlook, By Parenteral (2019-2028) ($MN)
Table 45 Global Ophthalmic Drugs Market Outlook, By Dosage Form (2019-2028) ($MN)
Table 46 Global Ophthalmic Drugs Market Outlook, By Solid Ophthalmic Drug Forms (2019-2028) ($MN)
Table 47 Global Ophthalmic Drugs Market Outlook, By Liquid Ophthalmic Drug Forms (2019-2028) ($MN)
Table 48 Global Ophthalmic Drugs Market Outlook, By Multicompartment Drug Delivery Systems (2019-2028) ($MN)
Table 49 Global Ophthalmic Drugs Market Outlook, By Semisolid Ophthalmic Drug Forms (2019-2028) ($MN)
Table 50 Global Ophthalmic Drugs Market Outlook, By Delivery Type (2019-2028) ($MN)
Table 51 Global Ophthalmic Drugs Market Outlook, By Eye Solutions (2019-2028) ($MN)
Table 52 Global Ophthalmic Drugs Market Outlook, By Capsules & Tablets (2019-2028) ($MN)
Table 53 Global Ophthalmic Drugs Market Outlook, By Eye Ointment (2019-2028) ($MN)
Table 54 Global Ophthalmic Drugs Market Outlook, By Gels (2019-2028) ($MN)
Table 55 Global Ophthalmic Drugs Market Outlook, By Eye Drops (2019-2028) ($MN)
Table 56 Global Ophthalmic Drugs Market Outlook, By Therapeutic Class (2019-2028) ($MN)
Table 57 Global Ophthalmic Drugs Market Outlook, By Anti-Inflammatory (2019-2028) ($MN)
Table 58 Global Ophthalmic Drugs Market Outlook, By Steroidal Drugs (2019-2028) ($MN)
Table 59 Global Ophthalmic Drugs Market Outlook, By Non-Steroidal Anti-Inflammatory drugs (NSAIDs) (2019-2028) ($MN)
Table 60 Global Ophthalmic Drugs Market Outlook, By Antibiotics (2019-2028) ($MN)
Table 61 Global Ophthalmic Drugs Market Outlook, By Anti-Allergy (2019-2028) ($MN)
Table 62 Global Ophthalmic Drugs Market Outlook, By Anti-Glaucoma Drugs (2019-2028) ($MN)
Table 63 Global Ophthalmic Drugs Market Outlook, By Prostaglandin Analogs (2019-2028) ($MN)
Table 64 Global Ophthalmic Drugs Market Outlook, By Combined Medication (2019-2028) ($MN)
Table 65 Global Ophthalmic Drugs Market Outlook, By Alpha Agonist (2019-2028) ($MN)
Table 66 Global Ophthalmic Drugs Market Outlook, By Beta-Blockers (2019-2028) ($MN)
Table 67 Global Ophthalmic Drugs Market Outlook, By Anti-Angiogenic (2019-2028) ($MN)
Table 68 Global Ophthalmic Drugs Market Outlook, By Anti-Infective Drugs (2019-2028) ($MN)
Table 69 Global Ophthalmic Drugs Market Outlook, By Anti-Fungal Drugs (2019-2028) ($MN)
Table 70 Global Ophthalmic Drugs Market Outlook, By Anti-Bacterial Drugs (2019-2028) ($MN)
Table 71 Global Ophthalmic Drugs Market Outlook, By Anti-Viral Drugs (2019-2028) ($MN)
Table 72 Global Ophthalmic Drugs Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) Agents (2019-2028) ($MN)
Table 73 Global Ophthalmic Drugs Market Outlook, By Retinal Drug (2019-2028) ($MN)
Table 74 Global Ophthalmic Drugs Market Outlook, By Other Therapeutic Classes (Cyclosporine) (2019-2028) ($MN)
Table 75 Global Ophthalmic Drugs Market Outlook, By End User (2019-2028) ($MN)
Table 76 Global Ophthalmic Drugs Market Outlook, By Specialty Clinics (2019-2028) ($MN)
Table 77 Global Ophthalmic Drugs Market Outlook, By Hospitals (2019-2028) ($MN)
Table 78 Global Ophthalmic Drugs Market Outlook, By Pharmacy (2019-2028) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
